Skip to main content

Petros Grivas

Dr. Petros Grivas is a medical oncologist at Seattle Cancer Care Alliance, Clinical Director of the Genitourinary Cancers Program, and Associate Professor at the University of Washington School of Medicine. He is also an Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center. 

His expertise is in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. Dr. Grivas currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer. 


  • Institutional research funding: Bavarian Nordic; BMS; Clovis Oncology; Debiopharm; Immunomedics; Pfizer; Merck; QED Therapeutics; GlaxoSmithKline; Mirati Therapeutics; Kure It Cancer Research
  • Consulting: AstraZeneca; Dyania Health; EMD Serono; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Genentech; Pfizer; Seattle Genetics

Latest contributions from Petros Grivas

Simon Crabb and Petros Grivas

08-03-2022 | ASCO GU 2022 | Conference coverage | Video

Simon Crabb and Petros Grivas share their highlights from ASCO GU

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

Petros Grivas | ASCO GU 2020

17-02-2020 | ASCO GU 2020 | Conference coverage | Video

Researcher comment: The ATLAS trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).